Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SG1906

Phase 1Small molecule

HHangzhou Sumgen Biotech Co., Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Unresectable or Metastatic Solid TumorsRecruiting

Locally Advanced Unresectable or Metastatic Solid TumorsPhase 1

Recruiting

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Locally Advanced Unresectable or Metastatic Solid Tumors

NCT05857332

Clinical

Trials by Indication[1]

Locally Advanced Unresectable or Metastatic Solid Tumors1 trial

A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG1906 in Patients With CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Solid Tumors.

Recruiting·HHangzhou Sumgen Biotech Co., Ltd.·Phase 1·NCT05857332·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SG1906. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SG1906 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SG1906. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hangzhou Sumgen Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: HHangzhou Sumgen Biotech Co., Ltd.

Related News